Exenatide is gLP-1 receptor agonist peptide (first in class). Exenatide was the first GLP-1 drug ever approved. It is a synthetic version of exendin-4, a peptide first found in Gila monster saliva. Sold as Byetta, it opened the door to today's GLP-1 medicines.
Education only. Not medical advice. No dosing information.
Status (verified Oct 29, 2026): FDA approved Apr 28, 2005 (Byetta, NDA 021773) for type 2 diabetes. Source: FDA approves Byetta (NDA 021773)
Evidence tier: FDA approved
Get alerts on legal status changes ->
What it is
Exenatide was the first GLP-1 drug ever approved. It is a synthetic version of exendin-4, a peptide first found in Gila monster saliva. Sold as Byetta, it opened the door to today's GLP-1 medicines.
How it works
It activates GLP-1 receptors to increase insulin release when blood sugar is high, lower glucagon and slow stomach emptying.
What it's researched for
Type 2 diabetes blood sugar control.
Where it shows up on Peptide Horizon
Regulatory and research timeline
- 2005-04-28: FDA approves Byetta (NDA 021773) (source)
Key trials and studies
FAQ
Is exenatide FDA approved?
Yes. Byetta was approved Apr 28, 2005, for type 2 diabetes.
Did exenatide really come from a lizard?
It is a synthetic version of exendin-4, a peptide discovered in Gila monster venom/saliva.
Is exenatide approved for weight loss?
No. Its approval is for type 2 diabetes.
Related peptides
- dulaglutide FDA status and research
- semaglutide FDA status and research
- pramlintide FDA status and research
Get alerts on legal status changes
Free email alerts when the FDA, HHS or another regulator changes the status of Exenatide or other peptides. Get alerts ->
Sources
Editorial review - Last reviewed Oct 29, 2026